Advanced search: Search from
Select basic information for advanced search
| Free word |
|---|
| Details |  |
|---|---|
| Related links |  |
| Search |  |
Papers (71)
- Masaya Nagamizu, Yuji Hotta, Masato Noda, Daigaku Nakamura, Masayuki Hori, Yuto Otsuka, Ryuhei Takemoto, Yasuhiro Horita, Eri Wakita, Nobuyuki Morishita, et al. Association of doses based on body constitutional parameters with the efficacy of micafungin in candidemia. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2025. 31. 4. 102654-102654
- Yoshihiko Tasaki, Shuzo Hamamoto, Shimpei Yamashita, Junya Furukawa, Kazutoshi Fujita, Ryotaro Tomida, Makito Miyake, Noriyuki Ito, Hideto Iwamoto, Yoshihisa Mimura, et al. Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study. Frontiers in Immunology. 2025. 15
- 三村 佳久, 内木 拓, 小田切 州広, 惠谷 俊紀, 権田 将一, 清水 伸彦, 青木 マリア, 森川 敏治, 冨田 実里, 田崎 慶彦, et al. 尿路上皮がん患者に対するアナモレリンの有効性と安全性 多施設共同無作為化比較試験. 日本癌治療学会学術集会抄録集. 2024. 62回. O27-5
- Moeko Iida, Yasuhiro Horita, Minami Asaoka, Kazuki Ohashi, Masato Noda, Chiharu Wachino, Toa Hirose, Yuki Nomura, Yoshinori Hisada, Masaya Nagamizu, et al. Evaluation of target area under the concentration-time curve of vancomycin in an initial dosing design: a retrospective cohort study. Journal of Antimicrobial Chemotherapy. 2024. 79. 10. 2518-2527
- 飯田 萌子, 堀田 康弘, 村松 桜子, 朝岡 みなみ, 野村 有紀, 大橋 一輝, 早川 智章, 河原 昌美, 堀田 祐志, 中村 敦, et al. バンコマイシン投与早期の急性腎障害予測因子の探索と2日目AUCの閾値推定. TDM研究. 2024. 41. 2. 162-162
- Akimasa Sanagawa, Tomoaki Hayakawa, Aya Yamamoto, Yuji Hotta, Yoko Furukawa-Hibi, Akimichi Morita. Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma. Drugs in R&D. 2024
- Shuzo Hamamoto, Yoshihiko Tasaki, Toshiharu Morikawa, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Rei Unno, Tomoki Takeda, Takashi Nagai, et al. Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma. Journal of Clinical Medicine. 2024. 13. 12. 3365-3365
- Daigaku Nakamura, Takeshi Yanagita, Yoshiaki Fujii, Kaori Watanabe, Takuya Suzuki, Hajime Ushigome, Ruriko Nishigaki, Naomi Sugimura, Mamoru Tanaka, Ryo Ogawa, et al. Unanticipated pathological clearance in two cases of clinical T4b dMMR/MSI-h advanced colorectal cancer: the potential of immune checkpoint inhibitors despite positive positron-emission tomography results. Surgical case reports. 2024. 10. 1. 105-105
- Yoshihiko Tasaki, Shuzo Hamamoto, Taku Naiki, Toshiki Etani, Shoichiro Iwatsuki, Rei Unno, Takashi Nagai, Yoshihisa Mimura, Yosuke Sugiyama, Yuji Hotta, et al. MP10-06 ELEVATED EOSINOPHILS BEFORE 2 COURSE TREATMENT MAY BE A UNIVERSAL BIOMARKER FOR IMMUNE-RELATED ADVERSE EVENTS INDUCED BY COMMON TO DIFFERENT IMMUNE CHECKPOINT INHIBITOR AND CANCER TYPES INCLUDING TO UROLOGICAL CANCER. Journal of Urology. 2024. 211. 5S
- Yoshihiko Tasaki, Nanami Ito, Yoshihisa Mimura, Yosuke Sugiyama, Ryo Ogawa, Takaya Shimura, Motoki Nakamura, Daisuke Kawakita, Shuzo Hamamoto, Takehiro Uemura, et al. Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients. Asia-Pacific journal of clinical oncology. 2024
- Yoshihiko Tasaki, Shuzo Hamamoto, Yoko Furukawa-Hibi, Takahiro Yasui. Effectiveness of switch therapy from tyrosine kinase inhibitors to immune checkpoint inhibitors: the need for biomarkers to establish treatment strategies in patients with metastatic renal cell carcinoma. Translational Andrology and Urology. 2024. 13. 4. 631-634
- Yoshihisa Mimura, Taku Naiki, Yosuke Sugiyama, Yoshihiko Tasaki, Kunihiro Odagiri, Toshiki Etani, Takashi Nagai, Moeko Iida, Yuka Kimura, Nanami Ito, et al. Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy. Cancer diagnosis & prognosis. 2024. 4. 4. 475-481
- Yuji Hotta, Kyoya Oyama, Takuma Yoshida, Naoya Ieda, Taiki Mori, Yasuhiro Horita, Tomoya Kataoka, Yoko Furukawa-Hibi, Susumu Ohya, Hidehiko Nakagawa, et al. The Effects of a Red-Light Controllable Nitric Oxide Donor, NORD-1, on Erectile Dysfunction in Rats with Streptozotocin Induced Diabetes Mellitus. The World Journal of Men's Health. 2024. 42
- Yoshihiko Tasaki, Yosuke Sugiyama, Shuzo Hamamoto, Taku Naiki, Takehiro Uemura, Keisuke Yokota, Daisuke Kawakita, Motoki Nakamura, Ryo Ogawa, Takaya Shimura, et al. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer medicine. 2023
- 杉山 洋介, 内木 拓, 三村 佳久, 田崎 慶彦, 片岡 智哉, 小田切 州広, 飯田 萌子, 木村 優花, 伊藤 菜浪, 権田 将一, et al. オキシコドンの血中濃度の変化とがん性疼痛との関連性の検討. 日本癌治療学会学術集会抄録集. 2023. 61回. O58-5
- 伊藤 菜浪, 三村 佳久, 田崎 慶彦, 杉山 洋介, 飯田 萌子, 小田切 州広, 木村 優花, 堀田 祐志, 日比 陽子. ニボルマブの異なる投与スケジュールにおけるirAE発症プロファイルの解析. 日本癌治療学会学術集会抄録集. 2023. 61回. P45-5
- 中村 大学, 小川 了, 菱谷 まどか, 朝岡 みなみ, 田中 達也, 堀田 祐志, 近藤 勝弘, 瀧口 修司, 日比 陽子. 食道癌治療のパラダイムシフト 外来FP+ICI療法の安全性についての検討. 日本癌治療学会学術集会抄録集. 2023. 61回. P44-2
- 三村 佳久, 杉山 洋介, 小田切 州広, 田崎 慶彦, 飯田 萌子, 木村 優花, 伊藤 菜浪, 堀田 祐志, 内木 拓, 惠谷 俊紀, et al. Cachexia indexは転移性尿路上皮がん患者の予後予測因子となる. 日本癌治療学会学術集会抄録集. 2023. 61回. O40-1
- 田崎 慶彦, 杉山 洋介, 伊藤 菜浪, 三村 佳久, 飯田 萌子, 小田切 州広, 木村 優花, 堀田 祐志, 内木 拓, 濱本 周造, et al. 好酸球は免疫チェックポイント阻害剤によるirAE発症の予測バイオマーカーとなる. 日本癌治療学会学術集会抄録集. 2023. 61回. MSA O58-3
- 杉山 洋介, 内木 拓, 三村 佳久, 田崎 慶彦, 片岡 智哉, 小田切 州広, 飯田 萌子, 木村 優花, 伊藤 菜浪, 権田 将一, et al. オキシコドンの血中濃度の変化とがん性疼痛との関連性の検討. 日本癌治療学会学術集会抄録集. 2023. 61回. O58-5
Return to Previous Page
